The patent's assignee for patent number 8653233 is
News editors obtained the following quote from the background information supplied by the inventors: "MUC1 is a large, transmembrane glycoprotein expressed on the apical surface of many types of polarized epithelia including pancreas, lung, breast and the gastrointestinal tract (Finn, et al. (1995) Immunol. Rev. 145:61). MUC1 is overexpressed and differentially glycosylated by a number of adenocarcinomas (Croce, et al. (1997) Anticancer Res. 17:4287) and has been evaluated as a candidate antigen for active immunotherapy protocols. Humoral and cell-mediated immune responses against MUC1 are detected in patients with MUC1.sup.+ tumors, as measured in vitro (Domenech, et al. (1995) J. Immunol. 155:4766; Petrarca, et al. (1999) Cancer Immunol. Immunother. 47:272; Nakamura, et al. (1998) J. Gastroenterol. 33:354); however, these responses are ineffective at eliminating the tumors in vivo.
"A number of MUC1-based immunogens have been evaluated as potential cancer vaccines (Graham, et al. (1996) Int.
"In vivo immune responses directed against tumor-associated MUC1 have also been analyzed. The nature of cellular immune responses that mediate rejection of MUC1-expressing tumors in mice was investigated by experiments that depleted CD4.sup.+, CD8.sup.+ or both T cell subsets in vivo. CD4.sup.+ cells were required for elimination of a human MUC1-expressing murine melanoma cell line (B16.MUC1), and CD8.sup.+ cells were required for the elimination of a human MUC1-expressing murine pancreatic carcinoma cell line (Panc02.MUC1), in wild-type C57BL/6 mice (Tempero, et al. (1999) Int.
As a supplement to the background information on this patent, NewsRx correspondents also obtained the inventors' summary information for this patent: "One aspect of the present invention is a MUC1 cytoplasmic tail peptide of SEQ ID NO:1 or a portion thereof for preventing or treating cancer in a subject. In a preferred embodiment, the MUC1 cytoplasmic tail peptide of SEQ ID NO:1 is part of a vaccine.
"Another aspect of the present invention is a method for preventing or treating cancer in a subject. The method involves administering to a subject an effective amount of a MUC1 cytoplasmic tail peptide of SEQ ID NO:1 or portion thereof so that cancer is prevented or treated in the subject."
For additional information on this patent, see: Hollingsworth,
Keywords for this news article include: Antigens, Tumors, Epitopes, Oncology, Peptides, Proteins, Cytoplasm, Immunology, Proteomics, Cancer Vaccines, Biological Products, Intracellular Space, Clinical Trials and Studies,
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC
Most Popular Stories
- Dmytro Firtash, Ukrainian Billionaire, Arrested in Vienna
- Obama, Ukraine Discuss Russian Incursion in Crimea
- Koch Brothers Step up Anti-Obamacare Campaign
- Obama's Overtime Initiative Praised, Condemned
- FDIC Sues Big Banks Over Rate Manipulation
- Liberty Media Drops Sirius Bid
- Republicans Warn Obama on Immigration
- Uli Hoeness, Bayern Munich President, Gets Prison for Tax Evasion
- West Readies Harsh Sanctions Against Russia
- Calumet Photo Files for Bankruptcy